E
ARMP icon

Ergoteles’s Armata Pharmaceuticals ARMP Stock Holding History

Ergoteles’s Portfolio ARMP Stock Details ARMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-24,585
Closed -$41.1K – 1036
2023
Q1 		$41.1K Sell
24,585
-3,356
-12% -$7.8K ﹤0.01% 1144
2022
Q4 		$34.6K Buy
+27,941
New +$72.8K ﹤0.01% 1322

Other funds holding ARMP

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return

Ergoteles's ARMP Position: Q2 2023 in Review

Ergoteles sold out of Armata Pharmaceuticals (ARMP) in Q2 2023, closing a stake of 24,585 shares — an estimated $41.1K sold.

Ergoteles first reported a position in ARMP in Q4 2022 and held it in 2 quarters. The position peaked at $41.1K in Q1 2023. 22 funds tracked by Wall St. Rank hold ARMP as of Q2 2023.

  • Ergoteles reported no remaining Armata Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 24,585 Armata Pharmaceuticals shares in Q2 2023, an estimated $41.1K.
  • Ergoteles first reported a position in Armata Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Ergoteles's Armata Pharmaceuticals position peaked at $41.1K in Q1 2023.
  • 22 funds tracked by Wall St. Rank held Armata Pharmaceuticals as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.